There is no fulltext present in this item.

Find Full text  
Title: Novel therapeutic targets in rheumatoid arthritis
Author(s): Koenders, M.I. ; Berg, W.B. van den
Publication year: 2015
Source: Trends in Pharmacological Sciences, vol. 36, iss. 4, (2015), pp. 189-195
ISSN: 0165-6147
DOI: http://dx.doi.org/10.1016/j.tips.2015.02.001
Publication type: Article / Letter to editor

Please use this identifier to cite or link to this item : https://hdl.handle.net/2066/153529   https://hdl.handle.net/2066/153529

Display more details
Subject: Radboudumc 5: Inflammatory diseases RIMLS: Radboud Institute for Molecular Life Sciences
Organization: Rheumatology
Journal title:
Trends in Pharmacological Sciences
Volume: vol. 36
Issue: iss. 4
Page start: p. 189
Page end: p. 195
Abstract:
Rheumatoid arthritis (RA) is an autoimmune disease that leads to inflammation and destruction of synovial joints. Despite the broad spectrum of antirheumatic drugs, this heterogeneous disease is still not well controlled in up to 30% of patients. Here, we discuss two pathways that are regarded as interesting novel therapeutic targets in the field of rheumatology: the Janus kinase (JAK) pathway and the T helper-17 (Th17) pathway [including interleukin (IL)-17, IL-21, IL-22, and granulocyte-macrophage colony-stimulating factor (GM-CSF)]. We also review the therapy potential of biologicals and small-molecule inhibitors blocking these pathways. Advances in combination therapy in addition to progress in biomarker screening will help us to further achieve effective and personalized healthcare for patients with RA.

This item appears in the following Collection(s)

Browse

Statistics